These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33588315)

  • 1. The presence of SARS-CoV2 antibodies in MS patients.
    Wallach AI; Picone MA
    Mult Scler Relat Disord; 2021 May; 50():102793. PubMed ID: 33588315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
    Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
    Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study.
    Vercellino M; Bosa C; Alteno A; Muccio F; Marasciulo S; Garelli P; Cavalla P
    Mult Scler Relat Disord; 2023 Jun; 74():104715. PubMed ID: 37058763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How the COVID-19 Pandemic has changed multiple sclerosis clinical practice: Results of a nationwide provider survey.
    Morrison EH; Michtich K; Hersh CM
    Mult Scler Relat Disord; 2021 Jun; 51():102913. PubMed ID: 33839482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review.
    Capone F; Motolese F; Luce T; Rossi M; Magliozzi A; Di Lazzaro V
    Mult Scler Relat Disord; 2021 Feb; 48():102734. PubMed ID: 33429305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    Mariottini A; Bertozzi A; Marchi L; Di Cristinzi M; Mechi C; Barilaro A; Massacesi L; Repice AM
    J Neurol; 2022 Jun; 269(6):2840-2847. PubMed ID: 35239006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.
    Simpson-Yap S; Pirmani A; Kalincik T; De Brouwer E; Geys L; Parciak T; Helme A; Rijke N; Hillert JA; Moreau Y; Edan G; Sharmin S; Spelman T; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton RM; Salter A; Bebo B; Van der Walt A; Butzkueven H; Ozakbas S; Boz C; Karabudak R; Alroughani R; Rojas JI; van der Mei IA; Sciascia do Olival G; Magyari M; Alonso RN; Nicholas RS; Chertcoff AS; de Torres AZ; Arrambide G; Nag N; Descamps A; Costers L; Dobson R; Miller A; Rodrigues P; Prčkovska V; Comi G; Peeters LM
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36038263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study.
    Zhang Y; Staker E; Cutter G; Krieger S; Miller AE
    Mult Scler Relat Disord; 2021 May; 50():102856. PubMed ID: 33662858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
    Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
    Front Immunol; 2020; 11():1059. PubMed ID: 32477373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of SARS-CoV2 on the anxiety levels of subjects and on the anxiety and depression levels of their parents.
    Dilek TD; Boybay Z; Kologlu N; Tin O; Güler S; Saltık S
    Mult Scler Relat Disord; 2021 Jan; 47():102595. PubMed ID: 33160138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study.
    Conte WL
    Mult Scler Relat Disord; 2021 Jul; 52():103014. PubMed ID: 34000684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
    Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
    Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
    ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
    Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
    Maillart E; Papeix C; Lubetzki C; Roux T; Pourcher V; Louapre C
    Mult Scler Relat Disord; 2020 Nov; 46():102482. PubMed ID: 32916509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.
    Alborghetti M; Bellucci G; Gentile A; Calderoni C; Nicoletti F; Capra R; Salvetti M; Centonze D
    Curr Neuropharmacol; 2022; 20(1):107-125. PubMed ID: 33784961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MSCOVID19: Using social media to achieve rapid dissemination of health information.
    Nesbitt C; Rath L; Yeh WZ; Zhong M; Wesselingh R; Monif M; Richards J; Minh VB; Jokubaitis VG; Skibina O; Butzkueven H; van der Walt A
    Mult Scler Relat Disord; 2020 Oct; 45():102338. PubMed ID: 32629402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab.
    Pedotti R; Muros-Le Rouzic E; Raposo C; Schippling S; Jessop N
    Mult Scler Relat Disord; 2021 Oct; 55():103203. PubMed ID: 34411984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series.
    Chisari CG; Toscano S; Arena S; Finocchiaro C; Montineri A; Patti F
    BMC Neurol; 2021 Nov; 21(1):462. PubMed ID: 34839814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.